Eblasakimab
Eblasakimab Significantly Alleviates IL-4 and IL-13-Induced Bronchial Airway Constriction in COPD-Derived Lung Slices
Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: A phase 1b, multiple-ascending dose study
Neuromodulation beyond itch is blocked by targeting IL-13Rα1 with eblasakimab
Combining Neuroscience And Immunology: Exploring The Neuro-immune Circuitry Behind Itch And Inflammation By Targeting IL-13Rα1With Eblasakimab
Exploring the potential of farudodstat, a DHODH inhibitor, as an alopecia areata therapeutic in a novel ex vivo model of human hair follicle immune privilege collapse
Downstream effects of IL-13Rα1 blockade on Th2-driven inflammation and Th1 immune axis activation in atopic dermatitis
Neuromodulation beyond itch is blocked by targeting IL-13Rα1 with eblasakimab
Eblasakimab Improves Multiple Disease Measures in Adult Patients with Moderate-to-severe Atopic Dermatitis in a Randomized, Double-blinded, Placebo-controlled, Phase 1 Study
Topline results from TREK-AD: a randomized, double-blind, placebo-controlled, Phase 2b study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis
For further details on the presentation, please refer to our press release.
Read More